Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. Necchi A, de Jong JJ, Raggi D, Briganti A, et al. Eur Urol 2021 Mar 27. pii: S0302-2838(21)00212.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Necchi A, de Jong JJ, Raggi D, Briganti A, et al. Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. Eur Urol 2021 Mar 27. pii: S0302-2838(21)00212.
PMID: 33785257